Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients.
Recombinant human erythropoietin was administered to 12 patients with end-stage renal failure on long-term hemodialysis. They responded to the therapy with a shortening of the prolonged bleeding time, starting from the 1st week of therapy, before a significant increase in hemoglobin concentration was achieved. We also observed an increase in the activity of tissue plasminogen activator and a decrease in the activity of its inhibitor. There were no changes in platelet count but a significant increase in blood and platelet serotonin concentration was found. The shortening of the prolonged bleeding time before the correction of the anemia correlated with the rise in blood and platelet serotonin concentration during erythropoietin therapy. We suggest the possible involvement of an serotonergic mechanism in the hemostatic action of recombinant human erythropoietin.
Malyszko
J
J
Department of Nephrology, Medical School, Bialystok, Zurawia, Poland.
Mazerska
M
M
Malyszko
J
J
Pawlak
K
K
Azzadin
A
A
Mysliwiec
M
M
Buczko
W
W
D000328:Adult; D000740:Anemia / Q000188:drug therapy*; D001760:Bleeding Time; D001792:Blood Platelets / Q000378:metabolism; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects* / Q000502:physiology; D006487:Hemostasis / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012701:Serotonin / Q000097:blood / Q000502:physiology*; D014511:Uremia / Q000188:drug therapy* / Q000503:physiopathology
D004921:Erythropoietin; D012701:Serotonin